Goldman Sachs
TPST icon

Goldman Sachs’s Tempest Therapeutics TPST Stock Holding History

Goldman Sachs’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-154
Closed -$53K – 5538
2020
Q2 		$53K Hold
154
– – ﹤0.01% 5062
2020
Q1 		$158K Buy
+154
New +$225K ﹤0.01% 4785
2015
Q4 		– Sell
-240
Closed -$5.96M – 7343
2015
Q3 		$5.96M Buy
240
+239
+23,900% +$16.1M ﹤0.01% 2726
2015
Q2 		$49K Buy
+1
New +$91.6K ﹤0.01% 6867

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's TPST Position: Q2 2021 in Review

Goldman Sachs sold out of Tempest Therapeutics (TPST) in Q2 2021, closing a stake of 107 shares — an estimated $25K sold.

Goldman Sachs first reported a position in TPST in Q4 2014 and held it in 17 quarters. The position peaked at $3.48M in Q4 2015. 23 funds tracked by Wall St. Rank hold TPST as of Q2 2021.

  • Goldman Sachs reported no remaining Tempest Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Goldman Sachs sold 107 Tempest Therapeutics shares in Q2 2021, an estimated $25K.
  • Goldman Sachs first reported a position in Tempest Therapeutics in Q4 2014 and held it in 17 quarters.
  • Goldman Sachs's Tempest Therapeutics position peaked at $3.48M in Q4 2015.
  • 23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.